Cannabis – Science vs Fiction

Jan 26, 2022 | Blog, Cannabis Science

Written by Christian Bogner, MD

The National Institutes of Health (NIH) is the primary agency of the United States government responsible for biomedical and public health research. Surprisingly, for the past half-century, the NIH has paid Israeli researchers millions of dollars to study the effects of medical cannabis. What has been the return on investment for that long-standing partnership? The American people have the right to know, right?

We live in a pivotal time in the cannabis revolution, once not too long ago under the gavel of Jeff Sessions, the Attorney General. His personal vendetta against the plant was so biased and aggressive, it almost seems surreal. “Good people don’t smoke Marijuana“. Also:

“I mean, we need grown-ups in charge in Washington to say marijuana is not the kind of thing that ought to be legalized. It ought not to be minimized, that it’s in fact a very real danger. Lives will be impacted. Families will be broken up. Children will be damaged because of the difficulties their parents have, and people may be psychologically impacted the rest of their lives with marijuana.”

Chuck Rosenberg, former head and current acting administrator at the Drug Enforcement Agency (DEA) thinks that “Medical cannabis is a joke.”

When there are 2.3 million patients in the US relying on the plant as their medicine (legally) [20], we need the best evidence there is to warn about dangers, but also teach about the benefits! Just recently I witnessed a child with an active seizure receive an intranasal spray that was cannabis-based. The seizure stopped within seconds. Medical cannabis is not a joke. There have been tremendous gains in understanding the medicinal properties of this plant in all of its divine molecular artistry. As of this year, several pharmaceutical “cannabis-like” synthetic drugs—all in the name of patents—have been approved with more than a half dozen to follow. And yet, the actual plant remains highly illegal from a federal vista.

Take Insys Therapeutics, for example. A pharmaceutical company that was one of the chief financial backers of the opposition to marijuana legalization in Arizona recently, received preliminary approval from the FDA for Syndros, a synthetic marijuana drug.

This begs the question:

ARE PHARMACEUTICAL COMPANIES EXPLOITING THE FEDERAL HEALTHCARE AGENCIES?

Read the rest of the article HERE